Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL555101 | 1.00 | ACE (0.41) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL698970 | 1.00 | ACE (0.41) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL23223889 | 0.94 | MEN1 (0.38) | ACE | |
| SCHEMBL157964 | 0.94 | MEN1 (0.38) | ACE | |
| SCHEMBL15904216 | 0.86 | — | — | |
| SCHEMBL16518728 | 0.85 | ACE (0.53) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL12658485 | 0.85 | ACE (0.53) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL12584754 | 0.81 | CNR1 (0.34) | — | |
| SCHEMBL14400492 | 0.81 | CNR1 (0.34) | — | |
| SCHEMBL8959051 | 0.81 | AR (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130324555-A1 | Method of use of pharmaceutical formulations for the treatment of apicomplexan diseases in animals | WOOD RICHARD DELAREY (US) | 2013-12-05 | — | — | US | claimed |
| US-20130150416-A1 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD D (US) | 2013-06-13 | — | — | US | claimed |
| US-20090239919-A1 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD DELAREY | 2009-09-24 | — | — | US | claimed |
| US-5770594-A | ANTICHOLESTEROL AGENTS, INHIBITORS OF CHOLESTEROL SYNTHESIS | PFIZER INC. (US) | 1998-06-23 | — | — | US | claimed |
| WO-1996020184-A1 | NAPHTHYL-BENZOXAZEPINES OR -BENZOTHIAZEPINES AS SQUALENE SYNTHETASE INHIBITORS | PFIZER INC. (US) | 1996-07-04 | — | — | WO | claimed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-111601798-A | Bisamide sarcomere activating compound and use thereof | 美国安进公司 | 2020-08-28 | — | — | CN | disclosed |
| US-8614205-B2 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD D (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130324555-A1 | Method of use of pharmaceutical formulations for the treatment of apicomplexan diseases in animals | WOOD RICHARD DELAREY (US) | 2013-12-05 | — | — | US | disclosed |
| US-20130150416-A1 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD D (US) | 2013-06-13 | — | — | US | disclosed |
| US-8211882-B2 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD DELAREY (US) | 2012-07-03 | — | — | US | disclosed |
| WO-2011103524-A2 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PEPTADERM SP.Z.O.O. (PL) | 2011-08-25 | — | — | WO | disclosed |
| US-7851439-B2 | EFTU inhibitors or aminothiazoles and their uses | NOVARTIS AG (CH) | 2010-12-14 | — | — | US | disclosed |
| US-20090239919-A1 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD DELAREY | 2009-09-24 | — | — | US | disclosed |
| US-20080221142-A1 | useful in interfering with the life cycle of bacteria and in treating or preventing a bacterial infection | NOVARTIS AG (CH) | 2008-09-11 | — | — | US | disclosed |
| US-5770594-A | ANTICHOLESTEROL AGENTS, INHIBITORS OF CHOLESTEROL SYNTHESIS | PFIZER INC. (US) | 1998-06-23 | — | — | US | disclosed |
| WO-1996020184-A1 | NAPHTHYL-BENZOXAZEPINES OR -BENZOTHIAZEPINES AS SQUALENE SYNTHETASE INHIBITORS | PFIZER INC. (US) | 1996-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239919-A1 | Glutamate receptor modulators and therapeutic agents | GRM5, GRM1, GRIK5 | ACE 2281/4885REN 944/4885LMNA 4247/4885 |
| US-20080221142-A1 | useful in interfering with the life cycle of bacteria and in treating or preventing a bacterial infection | LPO, PCNA, BPGM | ACE 1201/4885REN 2613/4885LMNA 1077/4885 |
| US-20130150416-A1 | Glutamate receptor modulators and therapeutic agents | GRM5, GRM1, GRIK5 | ACE 2375/4885REN 1833/4885LMNA 4491/4885 |
| US-20130324555-A1 | Method of use of pharmaceutical formulations for the treatment of apicomplexan diseases in animals | PIGS, ASAH2, ASAH1 | ACE 219/4885REN 1746/4885LMNA 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.